Browse the latest research summaries in the field of pharmacology for spinal cord injury patients and caregivers.
Showing 511-520 of 525 results
Spinal Cord Series and Cases, 2019 • June 26, 2019
This study explored the utilization of medicinal cannabis (MC) among individuals with spinal cord injury (SCI) to manage pain and other symptoms. The research compared current, past, and never users o...
KEY FINDING: Current and past MC users reported greater pain interference in daily life compared to never users.
PLoS ONE, 2013 • December 13, 2013
This study successfully isolated a recombinant antibody fragment (scFv) that binds to NCAM1-expressing cells in the intervertebral disc (IVD). This scFv has potential applications in targeted drug del...
KEY FINDING: A human scFv was successfully isolated against the recombinant NCAM1 domain using phage display technology.
Frontiers in Pharmacology, 2021 • July 20, 2021
bFGF is involved in all stages of pulp repair/regeneration and uses different intracellular signaling pathways to control specific biological processes, which may be determined by cell origins and trea...
KEY FINDING: bFGF acts through binding to tyrosine kinase FGF receptors on the cell membrane, triggering intracellular signaling pathways that initiate cell migration, proliferation, and differentiation.
Comp Biochem Physiol C Toxicol Pharmacol, 2015 • December 1, 2015
The study introduces a new tail regeneration model using late-stage Mexican axolotl embryos, which can regenerate amputated tails in 7 days. Chemical screening identified Wnt, transforming growth fact...
KEY FINDING: Axolotl embryos can completely regenerate amputated tails in 7 days without feeding, making them an efficient model for regeneration studies.
Neural Regeneration Research, 2017 • June 1, 2017
This study investigates the combined effect of brain injury and tacrolimus on peripheral nerve regeneration in rats with transected sciatic nerves. The results showed that combining brain injury with ...
KEY FINDING: Brain injury or tacrolimus alone, or their combination, alleviated muscle atrophy and nerve fiber impairment while improving sciatic nerve function.
Oncotarget, 2017 • March 3, 2017
This study investigates the effects of hydrogen-rich saline (HS) on testicular function in rats with hemisectioned spinal cord injury (hSCI). The results showed that hSCI significantly impaired hind l...
KEY FINDING: hSCI significantly decreased the hind limb neurological function, testis index, MSTD, and MSET, and induced severe testicular morphological injury.
The Journal of Spinal Cord Medicine, 2017 • March 1, 2017
This study highlights the high incidence of polypharmacy among individuals with spinal cord injury (SCI) and the associated increased risk of drug-related problems (DRPs). A significant percentage of ...
KEY FINDING: Patients with SCI were prescribed significantly more medications than their counterparts without SCI.
NEURAL REGENERATION RESEARCH, 2022 • October 1, 2022
This review discusses the critical roles of the mTOR pathway in axon regeneration in different types of CNS injury and demonstrates that the reactivation of this regenerative pathway can be achieved b...
KEY FINDING: mTOR signaling is the intrinsic axon regenerative pathway, and its reactivation can promote axon regeneration after adult CNS injury.
J Neurotrauma, 2012 • March 20, 2012
This systematic review evaluated the effects of pharmacological agents on walking function in individuals with spinal cord injury (SCI). The review found limited evidence supporting the use of pharmac...
KEY FINDING: One RCT provided Level 1 evidence that GM-1 ganglioside in combination with physical therapy improved motor scores, walking velocity and distance better than placebo and physical therapy in persons with incomplete SCI.
The Journal of Spinal Cord Medicine, 2018 • January 1, 2018
This case report describes the successful use of droxidopa in a patient with a spinal cord injury who had refractory orthostatic hypotension (OH) that was not responding to standard treatments. The pa...
KEY FINDING: Droxidopa increased blood pressure levels in the patient, specifically a 10 mm Hg increase in systolic BP and 6 mm Hg in diastolic BP in the supine position.